Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Resomelagon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resomelagon SCHEMBL30853066 | 1.00 | ALDH1A1 (0.45) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL28929658 | 1.00 | ALDH1A1 (0.45) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30862151 | 0.95 | RAB9A (0.44) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL23716726 | 0.95 | ALDH1A1 (0.43) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL12123680 | 0.95 | ALDH1A1 (0.43) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30084728 | 0.95 | ALDH1A1 (0.43) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL31103565 | 0.93 | RAB9A (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL28929656 | 0.93 | RAB9A (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30010038 | 0.93 | RAB9A (0.41) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 | |
| Resomelagon SCHEMBL30064309 | 0.93 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359076-B1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2025-08-06 | — | — | EP | claimed |
| EP-4359076-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SynAct Pharma ApS (DK) | 2024-05-01 | — | — | EP | claimed |
| WO-2022268825-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2022-12-29 | — | — | WO | claimed |
| US-20250387365-A1 | Combination Treatment Of Arthritic Disease | SYNACT PHARMA APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250302804-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SYNACT PHARMA APS (DK) | 2025-10-02 | — | — | US | disclosed |
| EP-4119140-B1 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES IN COMBINATION WITH METHOTREXATE FOR USE IN THE TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025124760-A1 | TREATMENT OF SUBPOPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-06-19 | — | — | WO | disclosed |
| US-12303489-B2 | Combination treatment of arthritic disease | SYNACT PHARMA APS (DK) | 2025-05-20 | — | — | US | disclosed |
| EP-4522160-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SynAct Pharma ApS (DK) | 2025-03-19 | — | — | EP | disclosed |
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2025-01-30 | — | — | US | disclosed |
| EP-4440572-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SynAct Pharma ApS (DK) | 2024-10-09 | — | — | EP | disclosed |
| CN-117836271-A | Salts of phenylpyrrolaminoguanidine and polymorphs of phenylpyrrolaminoguanidine onium salts | 西奈克制药有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023218048-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | SYNACT PHARMA APS (DK) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023094692-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | SYNACT PHARMA APS (DK) | 2023-06-01 | — | — | WO | disclosed |
| EP-4119140-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SynAct Pharma ApS (DK) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022268825-A1 | PHENYL PYRROLE AMINOGUANIDINE SALTS AND FORMULATIONS | SYNACT PHARMA APS (DK) | 2022-12-29 | — | — | WO | disclosed |
| US-20220211666-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2022-07-07 | — | — | US | disclosed |
| EP-3773558-B1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2022-06-15 | — | — | EP | disclosed |
| EP-3773558-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SynAct Pharma ApS (DK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020229297-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYNACT PHARMA APS (DK) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211666-A1 | COMBINATION TREATMENT OF ARTHRITIC DISEASE | SYVN1, AP1G1, DNPEP | ALDH1A1 2145/4885RAB9A 1873/4885NPC1 3649/4885 |
| US-20250032449-A1 | TREATMENT OF RHEUMATOID ARTHRITIS | MTX1, MTX2, SYVN1 | ALDH1A1 988/4885RAB9A 2233/4885NPC1 4061/4885 |
| US-20250302804-A1 | RESOMELAGON AND ITS DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASE, HYPERTENSION AND ATHEROSCLEROSIS | AGT, REN, EDNRB | ALDH1A1 3532/4885RAB9A 218/4885NPC1 1596/4885 |
| US-20250387365-A1 | Combination Treatment Of Arthritic Disease | ME1, SUCNR1, CPS1 | ALDH1A1 344/4885RAB9A 2436/4885NPC1 3280/4885 |
| US-12303489-B2 | Combination treatment of arthritic disease | SYVN1, AP1G1, DNPEP | ALDH1A1 2145/4885RAB9A 1873/4885NPC1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.